May 11, 2020 -- Biopharmaceutical company Themis and contract development and manufacturing organization ABL Europe announced that they have signed an agreement to manufacture a SARS-CoV-2 vaccine candidate in preparation for clinical trials.
The Themis vaccine candidate is being developed using measles virus vaccine platform technology, which is licensed exclusively to Themis by the Insitut Pasteur in Paris. ABL will manufacture the vaccine at its specialized facilities located in Strasbourg and Lyon, France.
Themis is actively collaborating with Institut Pasteur, the Center for Vaccine Research at the University of Pittsburgh, and the Coalition for Epidemic Preparedness Innovations (CEPI) to develop the COVID-19 vaccine candidate. CEPI initially has invested $4.9 million for its development.